Forte Biosciences, Inc. (FBRX)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
April 2026
Forte Biosciences, Inc. — 8-K Filing
# 🧾 What This Document Is This is an 8-K filing from Forte Biosciences, which is essentially a press release they sent to investors and the SEC. It's announcing their full-year 2025 financial results and giving an update on their drug development progress. Think of it as a company's "state of the u
SEC filings
All filings →Insider trades
All insider trades →Forte Biosciences, Inc. has no reported insider trades in the last 90 days.